polycystic ovary syndrome. Sclerocystic ovary syndromeStein-Leventhal syndrome
Conditions
Interventions
Intervention 1: the intervention group use cinnamon powder capsules three times a day and each time two 500- milligram capsules(a total of 3 grams per day) orally for two months. Intervention 2: contr
Treatment - Drugs
Placebo
the intervention group use cinnamon powder capsules three times a day and each time two 500- milligram capsules(a total of 3 grams per day) orally for two months
control group use cellulose capsule three times a day and each time two 500-miligram capsules (a total of three grams per day) orally for two months
Sponsors
shiraz universirty of medical sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: inclusion criteria:people who want to participate in study and full fill the informed consent form;Before choosing the sample, polycystic ovarian syndrome diagnosed by the gynecologist based on Rotterdam criteria;people have body mass index 25 or more;people age range is between18-40;have not Previous history of allergy to cinnamon consumption;do not have hypertension;do not have diabetes mellitus;do not have cardio vascular disease;do not have hepatic disease;do not have renal disease;do not have Cerebrovascular disease;do not have Seizure disorders;do not have Increased levels of the prolactin or other endocrine disorders;do not have Hypothyroidism or hyperthyroidism;do not have adrenal disorders;do not have cancer;do not have infertility;do not have history of alcohol use or smoking;do not use hormone therapy during three months prior to study;do not use hormonal contraception during three months prior to study;do not use insulin sensitizing drug during three months prior to study;do not be during pregnancy or breast feeding period; exclusion criteria do not want to continue the study;In case of any allergic symptoms after taking cinnamon;cinnamon consumption cut and will be excluded;In the event of pregnancy;cinnamon consumption cut and will be excluded;In case of loss of any inclusion criteria drug use will be cut and people excluded from the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body mass index. Timepoint: before intervention and after intervention. Method of measurement: Kilograms per height in square meters by the formula.;Weight. Timepoint: before study and after study. Method of measurement: kilogram by using scale.;Height. Timepoint: before intervention and after intervention. Method of measurement: centimetre by using metre.;Fasting glucose. Timepoint: before intervention and after intervention. Method of measurement: Milligrams per deciliter by use blood samples and laboratory testing.;Fasting insulin. Timepoint: before intervention and after intervention. Method of measurement: Micro units per milliliters of blood samples and laboratory testing.;Insulin resistance. Timepoint: before intervention and after intervention. Method of measurement: by using formula.;Oral glucose tolerance test. Timepoint: before intervention and after intervention. Method of measurement: Milligrams per deciliter by using blood sample and laboratory testing.;Cholesterol. Timepoint: before and after intervention. Method of measurement: Milligrams per deciliter by using blood samples and laboratory testing.;Low density lipoprotein. Timepoint: before and after intervention. Method of measurement: Milligrams per deciliter by using blood samples and laboratory testing.;High density lipoprotein. Timepoint: before and after intervention. Method of measurement: Milligrams per deciliter by using blood samples and laboratory testing.;Triglyceride. Timepoint: before and after intervention. Method of measurement: Milligrams per deciliter by using blood samples and laboratory testing. | — |
Secondary
| Measure | Time frame |
|---|---|
| Abdominal pain. Timepoint: before and during and after intervention. Method of measurement: Periodic follow-up by telephone call.;Itching. Timepoint: before and during and after intervention. Method of measurement: Periodic follow-up by telephone call.;Headache. Timepoint: before and during and after intervention. Method of measurement: Periodic follow-up by telephone call.;Hives. Timepoint: before and during and after intervention. Method of measurement: Periodic follow-up by telephone call.;Asthma. Timepoint: before and during and after intervention. Method of measurement: Periodic follow-up by telephone call.;Respiratory allergies. Timepoint: before and during and after intervention. Method of measurement: Periodic follow-up by telephone call.;Diarrhea. Timepoint: before and during and after intervention. Method of measurement: Periodic follow-up by telephone call.;Nausea. Timepoint: before and during and after intervention. Method of measurement: Periodic follow-up by telephone call.;Heartburn. Timepoint: before and during and after intervention. Method of measurement: Periodic follow-up by telephone call. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZeinab Moshfeghy
Fatemeh School of Nursing and Midwifery? Shiraz University of Medical Sciences
Outcome results
None listed